FIRST AMENDMENT TOLicense Agreement • November 6th, 2017 • Hong Kong
Contract Type FiledNovember 6th, 2017 JurisdictionWHEREAS, Gilead, MPP, and Licensee entered into that certain [Amended and Restated] License Agreement effective as of (the “Agreement”), pursuant to which MPP granted Licensee certain licenses with respect to Gilead’s proprietary pharmaceutical agents tenofovir alafenamide, tenofovir disoproxil fumurate, elvitegravir, and cobicistat for treatment of HIV and HBV in developing world countries; and